Class Action Lawsuit Filed Against uniQure N.V. Over Securities Fraud Allegations
A significant legal action has been initiated against uniQure N.V. (NASDAQ: QURE), a biotechnology firm specializing in gene therapies. A securities fraud class action lawsuit was filed by Kessler Topaz Meltzer Check, LLP on behalf of investors who acquired uniQure’s ordinary shares between September 24, 2025, and October 31, 2025. This class action, officially titled Scocco v. uniQure N.V., et al., is currently before the United States District Court for the Southern District of New York, underscoring the serious nature of the allegations and the potential implications for the company and its shareholders.
The complaint asserts that uniQure made materially false or misleading statements concerning its lead drug candidate, AMT-130, which is targeted at treating Huntington's disease. Throughout the designated class period, uniQure is accused of misrepresenting the status and design of the pivotal clinical trials associated with AMT-130. Allegedly, uniQure did not fully disclose that the design of its pivotal study had not received complete approval from the FDA, a critical detail that could significantly affect the drug’s pathways toward market approval.
Moreover, the lawsuit claims that the company downplayed the potential that it would need to delay the submission of its Biologics License Application (BLA) due to the necessity of further studies, thereby misleading investors regarding the timeline and viability of AMT-130’s approval. Crucially, on November 3, 2025, significant drops in share prices indicated that investors were blindsided when information regarding the FDA's position emerged. The share price plummeted by over 49%, marking a serious financial impact on those holding shares at the time.
As the legal landscape unfolds, investors are urged to take action. Those who purchased uniQure ordinary shares during the aforementioned time frame can file to be the lead plaintiff by the deadline of April 13, 2026. Being a lead plaintiff means having the authority to represent the interests of the entire class of investors who have been affected by the alleged misconduct.
KTMC encourages those who have suffered financial losses due to the alleged securities fraud to reach out for a free consultation regarding their legal rights and recovery options. This process entails selecting an attorney to lead the litigation effectively, and investors have the choice to either actively participate in the lawsuit or remain as absent class members.
As a biotechnology entity dedicated to innovating gene therapies, uniQure focuses particularly on solutions for rare diseases. Its work on AMT-130, which aims to slow down the debilitating effects of Huntington's disease, highlights the stakes involved, not just for the company but for the wider community reliant on such therapies.
As investigators delve deeper into the details of the case, it remains to be seen how this lawsuit will unfold and what consequences it may have for uniQure and its shareholders. Investors are strongly advised to stay informed and engage with legal counsel to understand their rights in light of this class action lawsuit. For further inquiries or to discuss specific concerns, Kessler Topaz Meltzer Check, LLP remains available to assist affected investors.
Background of the Allegations
The complaint asserts that uniQure made materially false or misleading statements concerning its lead drug candidate, AMT-130, which is targeted at treating Huntington's disease. Throughout the designated class period, uniQure is accused of misrepresenting the status and design of the pivotal clinical trials associated with AMT-130. Allegedly, uniQure did not fully disclose that the design of its pivotal study had not received complete approval from the FDA, a critical detail that could significantly affect the drug’s pathways toward market approval.
Moreover, the lawsuit claims that the company downplayed the potential that it would need to delay the submission of its Biologics License Application (BLA) due to the necessity of further studies, thereby misleading investors regarding the timeline and viability of AMT-130’s approval. Crucially, on November 3, 2025, significant drops in share prices indicated that investors were blindsided when information regarding the FDA's position emerged. The share price plummeted by over 49%, marking a serious financial impact on those holding shares at the time.
Implications for Investors
As the legal landscape unfolds, investors are urged to take action. Those who purchased uniQure ordinary shares during the aforementioned time frame can file to be the lead plaintiff by the deadline of April 13, 2026. Being a lead plaintiff means having the authority to represent the interests of the entire class of investors who have been affected by the alleged misconduct.
KTMC encourages those who have suffered financial losses due to the alleged securities fraud to reach out for a free consultation regarding their legal rights and recovery options. This process entails selecting an attorney to lead the litigation effectively, and investors have the choice to either actively participate in the lawsuit or remain as absent class members.
About uniQure N.V.
As a biotechnology entity dedicated to innovating gene therapies, uniQure focuses particularly on solutions for rare diseases. Its work on AMT-130, which aims to slow down the debilitating effects of Huntington's disease, highlights the stakes involved, not just for the company but for the wider community reliant on such therapies.
As investigators delve deeper into the details of the case, it remains to be seen how this lawsuit will unfold and what consequences it may have for uniQure and its shareholders. Investors are strongly advised to stay informed and engage with legal counsel to understand their rights in light of this class action lawsuit. For further inquiries or to discuss specific concerns, Kessler Topaz Meltzer Check, LLP remains available to assist affected investors.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.